A compound of formula I or II: in which: L is selected from -NHC - and -C NH-; Y 1 is selected from N and CH; Y 2 is selected from N and CH; Y 3 is selected from N and CH; Y 4 is selected from N and CR 8; wherein R 8 is selected from H, hydroxy-ethoxy, 3-hydroxyoxetan-3-yl, 2,3-dihydroxypropoxy, bis(hydroxy-ethyl)-amino, 4-hydroxy-piperidinl-yl, hydroxy-ethyl-amino, 4-amino-4-methylpiperidin-1-yl, 2-oxooxazolidin-3-yl, methoxy and methyl; Y 5 is selected from N and CR 1; or R 1 and the nitrogen of Y 4 form a 5 member unsaturated ring containing and additional heteroatom selected from N, O and S; or R 1 and R 8 together with the ring to which they are both attached form 2H-benzo[b][1,4]oxazin-3 -one substituted with one to two R 20 groups independently selected from methyl and hydroxy ethyl; or R 8 and Y 3 together with the ring to which they are both attached form 1H-benzo[d]imidazole substituted with methyl; R 1 is selected from H, ethoxy, isopropoxy, methoxy-ethyl-amino, (2-hydroxyethyl)(methyl)amino, (1-hydroxypropan-2-yl)amino, methoxy-ethoxy, hydroxy-ethoxy, methoxy, (2-hydroxypropyl)amino, (tetrahydro-2H-pyran-4-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, (1-ethylpiperidin-4-yl)oxy and pyrazolyl; wherein said pyrazolyl can be unsubstituted or substituted with 1 to 2 methyl groups; each R 2a is independently selected from hydrogen and OH; R 2b is selected from H, methyl, halo, fluoro-methyl, hydroxy, hydroxymethyl, difluoromethyl, formyl, methoxy and cyano; R 3 is selected from: wherein indicates the point of attachment with L; R 4 is selected from H, methyl, hydroxy-ethyl, hydroxy-propyl and 2,3-dihydroxypropyl; R 15 is selected from -CF 3, methoxy, -C(CH 3) 2 F, -CF 2 CH 2 F, -C(CH 3) 2 CN, -C(CH 3)F 2, -CHF 2, - C(CH 3) 2 OH, t-butyl, 1-cyanocyclopropyl, 2-(trifluoromethyl)cyclopropyl, -C(F 2)C 2 H 5, methylsulfonyl, 4-ethylpiperazin-1-yl, -C(CH 3) 2 NH 2 and dimethyl-amino-methyl; R 16 is selected from H, halo, hydroxy, dimethyl-amino, hydroxy-methyl, amino-methyl, - C(CH 3) 2 NH 2 and -CF 3; or a pharmaceutically acceptable salt thereof; with the proviso that a compound of formula II is not 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide or 2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide; or a pharmaceutically acceptable salt thereof. L is selected from -NHC - and -C NH-; Y 1 is selected from N and CH; Y 2 is selected from N and CH; Y 3 is selected from N and CH; Y 4 is selected from N and CR 8; wherein R 8 is selected from H, hydroxy-ethoxy, 3-hydroxyoxetan-3-yl, 2,3-dihydroxypropoxy, bis(hydroxy-ethyl)-amino, 4-hydroxy-piperidinl-yl, hydroxy-ethyl-amino, 4-amino-4-methylpiperidin-1-yl, 2-oxooxazolidin-3-yl, methoxy and methyl; Y 5 is selected from N and CR 1; or R 1 and the nitrogen of Y 4 form a 5 member unsaturated ring containing and additional heteroatom selected from N, O and S; or R 1 and R 8 together with the ring to which they are both attached form 2H-benzo[b][1,4]oxazin-3 -one substituted with one to two R 20 groups independently selected from methyl and hydroxy ethyl; or R 8 and Y 3 together with the ring to which they are both attached form 1H-benzo[d]imidazole substituted with methyl; R 1 is selected from H, ethoxy, isopropoxy, methoxy-ethyl-amino, (2-hydroxyethyl)(methyl)amino, (1-hydroxypropan-2-yl)amino, methoxy-ethoxy, hydroxy-ethoxy, methoxy, (2-hydroxypropyl)amino, (tetrahydro-2H-pyran-4-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, (1-ethylpiperidin-4-yl)oxy and pyrazolyl; wherein said pyrazolyl can be unsubstituted or substituted with 1 to 2 methyl groups; each R 2a is independently selected from hydrogen and OH; R 2b is selected from H, methyl, halo, fluoro-methyl, hydroxy, hydroxymethyl, difluoromethyl, formyl, methoxy and cyano; R 3 is selected from: wherein indicates the point of attachment with L; R 4 is selected from H, methyl, hydroxy-ethyl, hydroxy-propyl and 2,3-dihydroxypropyl; R 15 is selected from -CF 3, methoxy, -C(CH 3) 2 F, -CF 2 CH 2 F, -C(CH 3) 2 CN, -C(CH 3)F 2, -CHF 2, - C(CH 3) 2 OH, t-butyl, 1-cyanocyclopropyl, 2-(trifluoromethyl)cyclopropyl, -C(F 2)C 2 H 5, methylsulfonyl, 4-ethylpiperazin-1-yl, -C(CH 3) 2 NH 2 and dimethyl-amino-methyl; R 16 is selected from H, halo, hydroxy, dimethyl-amino, hydroxy-methyl, amino-methyl, - C(CH 3) 2 NH 2 and -CF 3; or a pharmaceutically acceptable salt thereof; with the proviso that a compound of formula II is not 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide or 2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide; or a pharmaceutically acceptable salt thereof.